Phaseline

Targets › EZH1

EZH1 (Histone-lysine N-methyltransferase EZH1): drug programs, companies and trials

3 programs from 3 companies in 11 trials: 7 Phase 1, 4 Phase 2; Oncology; next expected readout Jan 2028.

Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH1 complex, which methylates 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. (UniProt, Q92800)

Open in Phaseline: the race on EZH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Daiichi SankyoValemetostat Tosylate
EZH1/2 dual inhibitor
EZH1, EZH2, KDM1APhase 2Relapsed/Refractory Peripheral T-Cell Lymphoma; Non-small Cell Lung Cancer; Advanced Solid Tumor; Lymphoma, B-Cell …Mar 2028
Hanmi Pharmaceutical CompanyHM97662
EZH1/2 dual inhibitor
EZH1, EZH2Phase 1Advanced or Metastatic Solid TumorsJan 2028
NovartisTulmimetostat (DZR123, CPI-0209)
Dual EZH1/EZH2 inhibitor
EZH1, EZH2Phase 1Progressive Metastatic Castrate Resistant Prostate Cancer; Advanced Solid Tumor; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Mycosis FungoidesNov 2029

Conditions

Advanced Solid Tumor (2) Progressive Metastatic Castrate Resistant Prostate Cancer (1) Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (1) Mycosis Fungoides (1) Relapsed/Refractory Peripheral T-Cell Lymphoma (1) Non-small Cell Lung Cancer (1) Lymphoma, B-Cell (1) Castration-Resistant Prostate Carcinoma (1) Solid Tumor Malignancies (1) Advanced or Metastatic Solid Tumors (1)

Modalities

small molecule (3)

Companies

Novartis (1) Daiichi Sankyo (1) Hanmi Pharmaceutical Company (1)

Related targets

EZH2 (3) KDM1A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.